Abstract 3253
Background
Peptide receptor radionuclide therapy (PRRT) with 177Lutetium (177Lu) -DOTATATE is effective treatment for neuroendocrine tumors (NETs). Dosimetry assessment can be used to maximize the tumour dose, while keeping the dose delivered to critical organs to acceptable levels. The association between tumour absorbed dosimetry (TAD) and progression-free (PFS) and overall survival (OS) is not well understood.
Methods
Single institution retrospective analysis of patients with metastatic NET whom underwent up to 4 cycles of 7.45GBq 177Lu octreotate PRRT. Intra-therapeutic tumour dosimetry was performed with non-gated single photon emission computed tomography (SPECT) to quantify activity at 5 time points after administration of 177 Lu during cycle 1. TAD per injected activity (A0) and estimated total TAD (multiplied by total administered activity of 177Lu) was correlated with OS and PFS using the Kaplan–Meier method and Cox proportional-hazards model.
Results
79 patients were included, primary site: gastroenteric (48%), pancreatic (39%), bronchial (9%), other (4%), ECOG Performance status (PS) 0/1 (94%), Grade: G1 (47%), G2 (42%), G3 (11%), Ki-67≤20% (89%), concurrent chemotherapy use (29%). Mean TAD/A0 was 9(7-11) Gy/GBq. Progressive disease (54%) and death (29%) was seen. Median follow-up of 35 months. Median PFS was 32 [26-38] months. PFS was shorter with increasing ECOG PS (P = 0.02), tumour grade (P < 0.01), Ki-67 (P = 0.01), concurrent chemo-radionuclide therapy (P = 0.02) and reduced TAD (P = 0.036) but not primary site of origin (P = 0.66). A higher TAD led to an improved median PFS in pancreatic (P < 0.01) versus gastroenteric (P = 0.56) NETs. In a multivariate model incorporating ECOG PS, Ki-67 and chemotherapy use, total TAD remained significantly associated with PFS. The mean OS was 40 [36-44] months. OS was shorter with increasing tumour grade (P = 0.05), Ki-67 (P = 0.036) and reduced TAD (P = 0.039).
Conclusions
TAD was independently associated with OS and PFS validating dosimetry assessment in NET patients undergoing PRRT. Prospective refinement of the association on larger, more homogenous cohorts of NET patients is needed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5694 - Findings from a new specialist remote Counselling Service for Neuroendocrine Neoplasm (NEN) patients and family members
Presenter: Catherine Bouvier
Session: Poster Display session 2
Resources:
Abstract
4725 - Hematologic malignancies in temozolomide-treated metastatic pancreatic neuroendocrine tumors
Presenter: Nicole Balmaceda
Session: Poster Display session 2
Resources:
Abstract
5842 - Efficacy and toxicity of combination chemotherapy with cyclophosphamide, vincristine and an anthracycline in patients with metastatic extrapulmonary neuroendocrine carcinoma
Presenter: Leonidas Apostolidis
Session: Poster Display session 2
Resources:
Abstract
1543 - An Australian multi-centre experience of the use of peptide receptor radionuclide therapy for bronchial carcinoid tumours.
Presenter: Lisi Lim
Session: Poster Display session 2
Resources:
Abstract
4175 - Extra-pulmonary (EP) high grade (HG) neuroendocrine carcinoma (NEC): real-life outcomes of fifty-eight patients from a Portuguese cancer center.
Presenter: Rita Conde
Session: Poster Display session 2
Resources:
Abstract
3274 - Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNET)
Presenter: Shira Sherman
Session: Poster Display session 2
Resources:
Abstract
3534 - HORMONET: Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression
Presenter: Milton Barros
Session: Poster Display session 2
Resources:
Abstract
2137 - Clinical utility of Metabolic Tumor Volume in Papillary Thyroid Carcinoma
Presenter: Norihiko Takemoto
Session: Poster Display session 2
Resources:
Abstract
3864 - Correlation of thyroglobulin (Tg) oscillations with progression-free survival (PFS) in patients with radioactive iodine-refractory (RAI-R) differentiated thyroid carcinoma (DTC) treated with multikinase inhibitors (MKI).
Presenter: Jorge Hernando Cubero
Session: Poster Display session 2
Resources:
Abstract
2820 - Analytical validation of a thyroid cancer diagnostic method based on the relative quantification of CLDN10, HMGA2 and LAMB3 expression
Presenter: Mateus Barrosfilho
Session: Poster Display session 2
Resources:
Abstract